🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tackling chronic disease requires a comprehensive strategy that focuses on prevention and early intervention, health and wellness, and the development of new treatments and cures. Our CMO, Dr. Mike, shares how medicines can prevent disease and disease progression, helping to

Because of our IP system, the U.S. leads the world in medical breakthroughs. But this status relies on policies that support innovation and rein in the middlemen driving up costs. More in our latest with POLITICO: politico.com/sponsored/2025…

Nearly 800 CAR-T assets currently in the pipeline hold promise to improve patient outcomes with heightened efficacy and safety. Read how innovations like CAR-T are changing the game for patients: innovation.org/casestudy/car-…

Our industry remains focused on ensuring patient access to treatments by reining in middlemen who drive up costs and advocating for policies that foster innovation instead of stifling it. More from our CEO, Stephen J. Ubl:

Compounded drugs are not FDA approved and do not undergo FDA’s rigorous review to determine whether they are safe and effective. Our CEO Stephen J. Ubl explains how bad actors are exploiting the system and misleading patients while putting their health at risk to make a profit.

ICYMI: Important piece from The Washington Post: Innovative medicines are a bargain because they extend life, improve outcomes and prevent costlier care. Importing foreign price controls won’t help the system — it risks stalling it. washingtonpost.com/opinions/2025/…

.Bayer | Pharmaceuticals's Thomas Miller is excited about the growth of gene therapy and its potential to revolutionize care for those who have limited or no treatment options. More on how breakthroughs in medicine are creating a healthier America: innovation.org/breakthroughs/

The IRA’s drug price setting policies are hurting America’s seniors. A new Pioneer Institute analysis found that seniors are paying 32% more out-of-pocket on selected drugs as middlemen, like PBMs and insurers, hike copays, increase coinsurance & shift drugs to higher formulary

Today, there are more than 8,000 medicines in development with the potential to transform the lives of patients – all thanks to our strong IP system. Read more about the importance of U.S. leadership in biopharma innovation in our piece with POLITICO: politico.com/sponsored/2025…

At Semafor’s World Economy Summit, our CEO @SteveUbl discussed how the 340B program is a hidden tax on everyone and is driving up costs for patients. phrma.org/policy-issues/…

A new report illustrates how post-approval R&D is essential to not only delivering substantial health benefits to patients but economic benefits to society at large. phrma.org/blog/new-repor…

Today, researchers from our member companies met with lawmakers on Capitol Hill to advocate for policies that protect biopharmaceutical innovation and ensure patients can access the treatments they need to live healthier lives. We’re proud to support and elevate their voices.

This #AlzheimersandBrainAwarenessMonth, we recognize the profound toll brain diseases like Alzheimer’s take on patients, families and our health care system. America’s biopharmaceutical industry is committed to advancing innovative treatments that have promise to change the

Biopharma innovation over the last 25 years has led to significant advancements in health care and improvements in patient outcomes. Learn how breakthroughs in medicines are making a difference in the lives of countless patients: innovation.org/breakthroughs/

Why does the U.S. pay higher drug prices than other countries? Because 340B hospital markups and PBM middlemen drive up costs, while other countries don’t pay their fair share for the research and development of new cures. Learn more: phrma.org/policy-issues/…

Jocelyn Ulrich, MPH brings a rare blend of policy expertise and real-world insight to the table. As Vice President of Innovation Policy at PhRMA, she translates complex industry dynamics into actionable ideas that protect both innovation and the patients we serve. Her perspective is

DYK: Tax-exempt 340B hospitals can buy medicines for as little as a penny and then mark up the price by 1,000% or more? To lower costs, we must address the real problems in our system. Real solutions start here. phrma.org/blog/how-the-3…

Congratulations to the PhRMA Foundation on 60 years of funding future scientific leaders. Its impact cannot be understated: 97% of Foundation award recipients say receiving their funding increased their confidence and research potential, allowing them to conduct innovative

America is the only country that allows middlemen, like PBMs, to take half of every dollar spent on medicine. Foreign reference pricing fails to address the real reason drug prices are higher in the U.S. than in Europe. Hear more from our CEO Stephen J. Ubl at Semafor’s recent